Our Best Risk to Reward Idea Ever?
Adding Revive Therapeutics (RVVTF, RVV.CN) to the "2022, Biotech 12 Pack, 12 Biotech Stocks We Expect to...
Revive Therapeutics Updates, on Phase III Clinical Trial!
Michael Frank, CEO of the Company commented, "We are now in the final stages in our Phase 3 study.."
Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs
IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs
Glutathione: The “Mother” of all Antioxidants…
Glutathione, also known as GSH, is a molecule found naturally in your body. It is produced by the liver and nerve cells...
Revive Therapeutics (RVVTF, RVV): Updates and News Archive.
Recent Headlines
(See FDA Filing Submission at Bottom)
LIVE QUOTE
Institutional Analyst Newsletter. April 14, 2022.
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict
LIVE QUOTE
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
Report on Mitesco (MITI): Zacks Issues $0.53 Price Target, a 165% Potential Gain.
LIVE QUOTE
Original Report: Initiating Coverage...
Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...
New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
Surna Cultivation Technologies Signs $2.1 Million Contract
This is the 4th Multi-Million Contract Awarded in the Last Couple Years, With Three in 2022 Alone!